Palvella Therapeutics
PVLA
81 hedge funds and large institutions have $136M invested in Palvella Therapeutics in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 14 closing their positions.
736% more call options, than puts
Call options by funds: $903K | Put options by funds: $108K
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
8% more funds holding
Funds holding: 75 → 81 (+6)
0.02% more ownership
Funds ownership: 0.6% → 0.62% (+0.02%)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
18% less capital invested
Capital invested by funds: $165M → $136M (-$29.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$9.86M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$7.94M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$6.2M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.62M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$7.76M |
| 2 |
Millennium Management
New York
|
-$3.28M |
| 3 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$2.59M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$1.49M |
| 5 |
Morgan Stanley
New York
|
-$1.46M |
PVLA Hedge Fund Activity: Q4 2021 in Review
81 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2021, worth a combined $136M — down 18% from $165M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new PVLA positions and 14 closed out — a net gain of 7 holders — while 20 added to existing stakes and 22 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $9.86M. The largest seller was Invesco, exiting entirely with an estimated $7.76M sold.
- 81 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2021, up from 75 in Q3 2021.
- Funds reported $136M of Palvella Therapeutics stock for Q4 2021, down 18% quarter-over-quarter.
- 21 funds opened new Palvella Therapeutics positions in Q4 2021 and 14 closed out, a net change of +7 holders.
- The largest Palvella Therapeutics buyer in Q4 2021 was Woodline Partners, an estimated $9.86M added.
- The largest Palvella Therapeutics seller in Q4 2021 was Invesco, an estimated $7.76M sold.
Based on aggregated 13F filings for Q4 2021.